ABSTRACT BACKGROUND: Diabetic retinopathy (DR) is a blinding disease of increasing prevalence,
INTRODUCTION
Diabetic retinopathy (DR) is the leading cause of blindness in working age adults The diabetic complication rates of those living in remote Australia with limited access to healthcare are much greater, with a rate of vision threatening retinopathy between 7 and 11% [3] [4] [5] .
Landmark trials over the last 30 years have been crucial in substantiating an association between the development and progression of DR and risk factors including diabetes mellitus (DM) duration, glycemic control, hypertension and hyperlipidemia [6] [7] [8] . The focus of recent research on DR susceptibility has moved to the contribution of genetic susceptibility to DR development and severity. The Diabetes Control and Complications Trial (DCCT) was the first large-scale trial to investigate and determine a significant correlation between patients and their first-degree relatives in relation to the presence and severity of DR, independent of glycemic control 9 . Significant familial aggregation of DR severity across a range of ethnic groups was subsequently demonstrated, with the degree of heritability dependent on ethnicity 10 . The heritable component of sight-threatening DR has been reported to be between 25% and 50% 10, 11 . Genome-wide association studies (GWAS) have been conducted to investigate the genetic contribution to DR susceptibility, but to date, results have not been reproducible across studies and studies have lacked appropriate statistical power to detect variants of even modest effect size 12, 13 . A number of functional candidate genes for DR susceptibility have Archived at Flinders University: dspace.flinders.edu.au been studied, including aldose reductase (ALR), angiotensin converting enzyme (ACE), vascular endothelial growth factor (VEGF) and nitric oxide synthase (NOS) 14 . The efficacy of inhibiting the VEGF pathway in the treatment of diabetic macula edema (DME) demonstrates the clinical relevance of research aimed at elucidating the genetic risk factors, and the associated molecular pathways involved in the pathogenesis of sightthreatening DR. Such improved understanding is required to facilitate the development of personalized approaches, and novel therapeutic strategies to reduce the burden of diabetes associated visual morbidity.
The sample presented in this paper is a current representation of Australian type 1 (T1) and type 2 (T2) diabetes patients from an era in which the importance of glycemic control and systemic vascular risk factors have been well understood. The target population includes individuals with DM affected by potentially sight-threatening complications of DM, as well as individuals who have DM without retinopathy. The eventual outcome of this study is to investigate the influence of genetics on the development and severity of DR, specifically using GWAS methodology to identify candidate single-nucleotide polymorphisms (SNPs). An understanding of the molecular pathogenesis of DR would have significant implications for screening strategies and the development of novel therapies. The present report describes the recruitment methodology, case control definitions, and the clinical characteristics of the sample to be studied.
METHODS

Ethics approval:
In South Australia, ethics approval was obtained from the Southern Adelaide Health London, United Kingdom) has become the first international recruitment centre for this study. Recruitment from this site, along with participants from ongoing recruitment throughout Australia will be used for replication analysis following GWAS.
Ophthalmology, endocrinology and renal clinics of these hospitals were used to identify and recruit participants with diabetes meeting eligibility criteria. A combination of sequential recruitment, and opportunistic recruitment with a bias towards patients with more severe diabetic complications occurred. Written, informed consent was obtained from all participants following explanation of the nature and possible consequences of the study.
Archived at Flinders University: dspace.flinders.edu.au
Case and control definitions
Eligibility criteria for this study required that participants were at least 18 years of age and had either T1DM of any duration, or T2DM of at least 5 years duration. All participants must be taking oral hypoglycemic medication, or be on insulin therapy, or both. Individuals with diet-controlled DM were excluded.
Cases included those with sight threatening DR, meeting at least 1 of the following criteria:
1. Worst ever retinopathy grading of severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) in at least 1 eye; 2. The presence or history of DME in at least 1 eye.
Controls were defined as those whose retinopathy grading had never been worse than minimal NPDR, and who had no current or previous history of DME in either eye. Those with mild or moderate NPDR were recruited for the longer term study of issues such as progression, but excluded from specific analyses comparing cases and controls for the purpose of the planned GWAS.
Clinical data collection:
Full ophthalmic examination was performed according to existing site specific clinical practice. Acuity was assessed with either Snellen or logMAR charts, and recorded in the database as Snellen equivalent. Examination of the anterior segment included specific assessment of any lens opacity, and also the presence or absence of rubeosis. . Worst ever retinopathy status for the worse eye was used in the analyses.
Participants were classified as having DME irrespective of their DR grading if they were found to have DME in either one or both eyes. Those who had received laser treatment or intravitreal injections for sight-threatening DR were graded according to their retinopathy status prior to treatment (ie their worst ever grading). Participants with active disease were documented with color photography, fundus fluorescein angiography (FFA), and optical coherence tomography (OCT) of the macula as clinically indicated at the discretion of the treating clinician, but the clinical grading as determined at the time of slit lamp biomicroscopy was used for classification. Ophthalmologists were contacted to obtain ophthalmic examination data of participants recruited who attended private ophthalmology clinics.
For individuals in whom FFA was clinically indicated, a digital mydriatic retinal camera was used to obtain retinal photographs. Prior to photography, pupils were further dilated with phenylephrine hydrochloride 2.5%. Macular OCT, including high definition macular scans, was performed for all patients with DME using a Cirrus HD-OCT (Carl Zeiss Meditec, California, USA). Patients who had a history of previous laser treatment but with currently inactive disease were not subjected to photography or OCT.
A detailed questionnaire was administered to collect relevant information regarding social, demographic and medical history. Information collected included sex, age, ethnicity and lifestyle factors (cigarette smoking and alcohol history). Medical history data included DM type and duration, family history of DM, co-existing risk factors (systemic hypertension, hypercholesterolemia), history of vascular disease (ischemic heart disease (IHD), cerebrovascular accident (CVA) or transient ischemic attack (TIA), peripheral vascular disease (PVD)), and history of diabetic complications (peripheral neuropathy, diabetic nephropathy and details of renal transplant or dialysis). Ophthalmic history was completed by the treating ophthalmologist and included details of past cataract surgery, age related macular degeneration (ARMD), glaucoma, retinal detachment, vitreous hemorrhage, rubeosis/iris neovascularisation and past treatment for DR (focal laser, macular grid laser, pan retinal photocoagulation (PRP), intravitreal injections, and vitrectomy). The year of development of sight-threatening DR was also documented.
Height, weight and blood pressure measurements were taken at the time of recruitment.
Individuals were classified as having hypertension if they were on pharmacologic treatment for hypertension, or they had a systolic or diastolic blood pressure reading greater than or equal to 140mmHg or 90 mm Hg respectively. 
Collection of DNA and serum:
A venous blood sample was obtained from each participant by a trained venipuncturist.
Two 9ml Vacuette EDTA tubes of venous blood were collected and stored at 4 degrees Celsius. DNA was extracted from the blood samples using the QiaAmp Blood Maxi Kit (Qiagen, Valencia, California). An 8ml Vacuette serum tube was also collected from a subset of approximately half the participants when the proximity of the recruitment site facilitated the timely processing of the sample. These serum tubes were centrifuged at 2700g for 10 mins within 2 hours of collection. The serum was transferred to 1ml microfuge tubes, labeled and stored at -80 degrees Celsius for future analysis.
Data analysis:
All data recorded onto the data collection form were entered into a password protected . Case and control groups were compared for differences in age and sex with a Mann-Whitney U test and a chi-squared test respectively. Data was characterized using basic descriptive statistics, and correlations between variables and phenotypes were assessed. Variables were analysed for differences between DM type using the Mann-Whitney U test and a chi-squared test. Analyses were considered for sight-threatening DR, PDR and DME subgroups, for T1DM and T2DM combined, and also stratified for type of DM. P values <0.05 were considered statistically significant. Odds ratios (OR) are presented with corresponding 95% confidence intervals. Power calculations were made with the online program Genetic Power Calculator 16 .
RESULTS
Cases and controls
A total of 1669 Caucasian individuals with DM were recruited for inclusion in GWAS analysis. Included were 683 cases with sight threatening DR and 812 diabetic controls as defined in methods. Of the cases, 215 patients with DME also had co-existing PDR or severe NPDR. A further 174 (10%) participants had DR that met neither sight threatening case or control criteria (ie. mild or moderate NPDR) for the purpose of the genome-wide association study. The sample comprised 407 (24%) T1DM and 1262 (76%) T2DM patients. Retinopathy gradings by type of DM are presented in table 1.
Baseline characteristics of case and control groups were compared (Table 2) . A Chisquare test for independence (with Yates Continuity Correction) indicated significantly more male cases compared with controls for T2DM alone (χ 2 =6.9, p=0.008), and all DM irrespective of type (χ 2 =9.97, p=0.002). Age distribution was found to violate the assumption of normality for T1DM and T2DM patients alone and combined. A MannWhitney U Test revealed no significant difference in age between case and control groups when pooling all diabetics (p=0.196). Analysis by DM type found that T1DM controls were significantly younger than cases (U=11957.5, p<0.001), but that T2DM controls were significantly older than cases (U=137741, p=0.001). The baseline differences found between case and control groups will be accounted for in multivariate models for future analyses.
Clinical variables
Duration of DM ranged from 0-70 years with a mean duration of 18 years. The prevalence of co-morbidities was high, with 76% of participants having hypertension, 66% of participants having hyperlipidemia, and a mean body mass index (BMI) of 30.8 (range 14.3-70.5; SD 6.6). Suboptimal diabetic control as determined by HbA1C was also common, with the sample having a mean HbA1C of 8.1% (range 2.2-15.3%; SD 1.6).
Duration of diabetes, total cholesterol, systolic blood pressure, HbA1C and BMI were all unimodally distributed.
Complications of DM (DR, nephropathy, neuropathy, IHD or stroke) were noted in 80% (1331 patients) of the sample. Of 741 patients who had urine albumin measurements available, 38% had nephropathy (26% with microalbuminuria, and 13% with macroalbuminuria), with 17 of these patients on dialysis and 5 having received renal transplants. 29% of patients had neuropathy, 24% had ischemic heart disease and 9% had a history of stroke. Clinical characteristics stratified by DM type are presented in table 3, with p-values comparing these variables between T1DM to T2DM participants.
The correlation of clinical variables with type of DR was also examined (Table 4) . Sight threatening DR, PDR and DME were assessed in separate models. Statistically significant (P < 0.05) correlations with one or more subgroups of DR were found for duration of diabetes, diabetes type, hypertension, nephropathy, neuropathy, HbA1C and BMI.
Correlations were strongest for HbA1c, duration of diabetes, and nephropathy.
Interestingly, PDR was correlated with T1DM (p<0.001), whereas DME was correlated with T2DM (p<0.001).
Power
Power for the planned GWAS was calculated using a specific type 1 error rate of 5x10 Aldose reductase, involved in the polyol pathway, consumes NADPH while reducing glucose to sorbitol, and in turn contributes to microvascular damage through the exacerbation of intracellular oxidative stress 18 . The AKR1B1 gene has been investigated in a number of ethnic groups and DM types with varying findings. The z-2 allele of a short tandem repeat microsatellite marker has been associated with increased risk of DR in both T1DM and T2DM, whereas the z+2 allele has been shown to be protective against retinopathy in T1DM
14
. However, more recent multivariate analysis which accounted for confounding risk factors (including duration of DM and glycemic control), did not confirm these associations between the AKR1B1 gene and DR, 19 indicating confounding factors contributing to the reported associations. No studies to date have specifically investigated the contribution of this gene to the development of DME.
VEGF has been shown to contribute to the development of diabetic microvascular complications including DR and DME through its role in angiogenesis, and the associated increase in vascular permeability 20 . A number of GWAS and candidate gene studies have reported associations of various VEGFA SNPs, though results have not been consistent between studies 14 . Two particular SNPs that combined represent nearly 50% of the VEGF variance have been assessed in a large case control study including 6920 T2DM
participants, but neither appeared to be directly associated with the development of DR, DME or diabetic nephropathy (DN) 21 . The clinical benefit of intravitreal anti VEGF therapy for PDR and DME is now well substantiated 22, 23 , however the complex genetic link between VEGF and diabetic microvascular complications may be indirect and requires further detailed investigation.
Suboptimal power also remains problematic in recent GWAS, and as a result, genome wide significance has not been reached in any published study, nor has there been any consistency in genes identified between studies 11, [24] [25] [26] . Studies so far have typically included samples from the entire range of DR severity, with case-control definitions comparing no DR with any DR 24 , or any DR with severe DR 11, 25 . Given that the DR variants under investigation are likely to have small to moderate effect sizes, large sample sizes are required in order to reach statistical significance when using population sampling. However, there is good recent evidence to suggest that focusing on recruitment and analysis of phenotypic extremes results in systematically larger effect sizes than the overall population effect size 27 . This strategy has specifically been used in the discovery of rare variants, and is postulated to reduce the required sample size by as much as fourfold compared with sampling from the general population 27 . The case-control definitions adopted for the current study differ from GWAS performed to date by involving analysis of phenotypic extremes. We have successfully employed this strategy using advanced glaucoma cases to detect two genome wide significant loci in a study of 650 cases 28 . We expect results of the current study to be consistent with a sufficiently powered GWAS and the potential for detection of susceptibility loci for DR.
Data from long-term prospective population based studies indicate that those with T2DM may be more susceptible to DME than those with T1DM, and that the difference in the incidence of DME between these groups becomes more pronounced as duration of DM increases 29, 30 . Preliminary descriptive statistics of the present study sample are consistent with this finding, with double the prevalence of DME in T2DM compared with T1DM
participants. The implication of this association during an era of rapidly increasing incidence of T2DM, on vision related quality of life and health care costs is particularly noteworthy. DME is the major vision threatening complication of DR and thus determining independent genetic risk factors for DME is imperative in achieving improved treatment strategies and outcomes.
The complex integration between genetic susceptibility and environmental risk factors in the development of diabetic microvascular complications requires further investigation with large sample sizes and clear a priori case and control definitions in order to obtain meaningful results. Specific analysis of DME is warranted given the lack of current understanding of the genetic risk factors involved, and the associated visual morbidity of this type of DR. The size of the current sample has the capacity to detect genome wide significance. The potential outcome of this study is the identification of candidate genes involved in the development and progression of PDR and DME, to assist in the development of novel management strategies targeting this blinding disease of increasing prevalence. retinopathy; DME, diabetic macular edema. Sight-threatening DR is defined as severe NPDR or PDR and/or DME.
TABLES:
